The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).
The Canadian government has responded to Eli Lilly’s complaint that recent decisions to invalidate two Lilly patents violated the North American Free Trade Agreement, saying that Lilly’s challenge is “wholly without merit”, and should be dismissed.
The UK government’s “patent box” was a key factor behind the multi-billion pound cash-plus-shares takeover bid for the Irish-headquartered global specialty biopharmaceutical company Shire by US-based drugs company AbbVie.
Johnson & Johnson’s senior vice president of IP, Phil Johnson, may be out of the running for the top job at the US Patent and Trademark Office (USPTO) as the Obama administration reconsiders its choice for the role, insiders have told The Wall Street Journal.
Pfizer is facing three class actions that allege the pharmaceutical company improperly obtained a patent covering its arthritis drug Celebrex (celecoxib) and used it to force generic drug makers into settlements that delay their entry into the market, Law360 has reported.
French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
US-based Acorda Therapeutics has sued Actavis for infringing four patents covering its multiple sclerosis (MS) drug Ampyra (dalfampridine).
Tennessee-based law firm Stites & Harbison PLLC has expanded its IP and technology practice with the hire of life sciences partners Kelly Hollowell and Justin McNaughton.
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.
An ex-employee for a large Chinese seed production company has been arrested in the US for conspiring to steal trade secrets from US agricultural companies including Monsanto.